Kiniksa Pharmaceuticals International, Plc · NASDAQ:KNSA
Kiniksa Pharmaceuticals International — Q4 2025 Earnings Presentation
14 slides from Kiniksa Pharmaceuticals International's earnings presentation, Feb 24, 2026
Slide 1: Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution
Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution F E B R UA R Y 2 4 , 2 0 2 6
Slide 2: Agenda
Agenda Introduction | Sanj K. Patel, Chief Executive Officer IL-1α & IL-1β Inhibition Franchise | Ross Moat, Chief Operating Officer Fourth Quarter and Full Year 2025 Financial Results | Mark Ragosa, Chief Financial Officer Closing Remarks | Sanj K. Patel, Chief Executive Officer Q&A Session 2
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements with respect to Kiniksa Pharmaceuticals International, plc (and its consolidated subsidiaries, collectively, unless context oth
Slide 4: Introduction
Introduction Sanj K. Patel Chief Executive Officer
Slide 5: Q4 and Full Year 2025 Business Highlights
Q4 and Full Year 2025 Business Highlights Driving ARCALYST Maintaining Financial Advancing Clinical Portfolio Revenue Strength Q4 2025 ARCALYST revenue KPL-387 granted Orphan Strong financial position of $202.1M Drug Designation for with ~$414M in cash pericarditis Full year 2025 ARCALYST Current op
Slide 6: Building on Established Leadership in Recurrent Pericarditis
Building on Established Leadership in Recurrent Pericarditis ARCALYST Expanding Franchise with • First-and-only FDA-approved therapy Compelling Value Proposition • Enabled paradigm shift in US recurrent pericarditis treatment as a steroid-sparing therapy • Utilizing a validated approach of dual IL-1
Slide 7: IL-1α & IL-1β Inhibition Franchise
IL-1α & IL-1β Inhibition Franchise Ross Moat Chief Operating Officer
Slide 8: Expanding Adoption of IL-1α & IL-1β Inhibition Driving ARCALYST Sales
Expanding Adoption of IL-1α & IL-1β Inhibition Driving ARCALYST Sales Kiniksa has established the Recurrent Pericarditis market with line of sight to future blockbuster status Launch → 2025 $900-920M 2026 → Establishing the Recurrent Pericarditis Market Expected Net Unlocking the Next Phase of Growt
Slide 9: Strong Commercial Fundamentals Support Continued ARCALYST Growth
Strong Commercial Fundamentals Support Continued ARCALYST Growth $677.6M >4,1501 Full Year 2025 Net Revenue Total Prescribers Representing ~62% YoY Growth ~1,200 Repeat Prescribers ~3 Years1 ~18% 1 Average Total Duration of Therapy Growing and Approaching Penetration into Multiple Recurrence Median
Slide 10: Driving Penetration in Initial Target Population with Upside Opportunity
Driving Penetration in Initial Target Population with Upside Opportunity ARCALYST Label Covers Recurrent Pericarditis (Annual Epidemiology of Approximately 40,000) Increasing Penetration into Multiple Recurrence 1st Recurrence Population ~26,000 ~20% of patients on ARCALYST A sizable portion could b
Slide 11: Financials
Fourth Quarter and Full Year 2025 Financials Mark Ragosa Chief Financial Officer
Slide 12: Fourth Quarter and Full Year 2025 Financial Results
Fourth Quarter and Full Year 2025 Financial Results Three Months Ended Year Ended Three Months Ended Year Ended Income Statement December 31, December 31, Collaboration Expenses1,2 December 31, December 31, 2025 2024 2025 2024 2025 2024 2025 2024 Product Revenue $202.1M $122.5M $677.6M $417.0M ARCAL
Slide 13: Closing Remarks
Closing Remarks Sanj K. Patel Chief Executive Officer
Slide 14: Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution
Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution F E B R UA R Y 2 4 , 2 0 2 6
Kiniksa Pharmaceuticals International — Q4 2025 Earnings Presentation on 6ix